The Institute of Molecular Biology and Genetics announced the positive results of the first stage of clinical trials for the treatment of severe coronavirus pneumonia with stem cells. The press service of the institute announced this on Facebook.
"Good news: the results of the first stage of clinical trials for the treatment of severe coronavirus pneumonia, namely the so-called cytokine storm, with stem cells have been obtained," the statement reads.
The study included 13 patients (men aged 36 to 73 years) with bilateral pneumonia, saturation below 93 percent and severe disease.
According to the institute, in the second week after the introduction of stem cells, the lungs of four of 13 patients fully recovered.
In the control group of 15 patients who did not receive cell therapy, one person died, seven had manifestations of pulmonary fibrosis at the eighth week.
"These data allow us to assert that today the use of mesenchymal stem cells is a promising method of combating fibrotic degeneration of lung tissue as a result of pneumonia caused by the SARS-CoV-2 coronavirus," a senior researcher at the Institute of Molecular Biology and Genetics Vlolodymyr Shabliy said.
Mesenchymal stem cells are used in treatment. Their peculiarity is that after transplantation, such cells, which do not have a previous "specialization", are able to turn into the necessary tissues.
Meanwhile, South Korean authorities are investigating the deaths of two people, who died within days of receiving AstraZeneca’s Covid-19 vaccine.
AstraZeneca said it was aware of the investigation by the Korea Disease Control and Prevention Agency (KDCA), but the safety of the vaccine has been extensively studied in clinical trials with data confirming it is generally well tolerated.